All contributors
Onconephrology contributor
Perazella, Mark A
Primarily Anticancer drug nephrotoxicity#11 of 47 recognizedHonor roll
- #2 in Onco-nephrology (general)
- #2 in Anticancer drug nephrotoxicity
46
Clinical papers
2,544
Citations (iCite)
13 / 27
First / senior author
2002–2026
Active years
Output over time
Clinical corpus papers per year — peak 6 in 2018.
- 2002: 1 paper
- 2009: 1 paper
- 2010: 1 paper
- 2012: 1 paper
- 2014: 3 papers
- 2015: 3 papers
- 2016: 5 papers
- 2017: 4 papers
- 2018: 6 papers
- 2019: 5 papers
- 2020: 3 papers
- 2021: 2 papers
- 2022: 4 papers
- 2023: 1 paper
- 2025: 1 paper
- 2026: 5 papers
20022026
Subfield mix
Clinical papers by onconephrology subfield (a paper can count in more than one).
Anticancer drug nephrotoxicity33
Onco-nephrology (general)18
Checkpoint-inhibitor kidney injury10
Myeloma cast nephropathy5
Cellular therapy renal effects4
Anti-VEGF / TKI renal effects2
MGRS & paraprotein kidney disease2
Tumor lysis & electrolytes1
Frequent collaborators
Other recognized contributors who most often share corpus papers with Perazella (shared-paper count).
Agents they study
Catalog agents whose clinical kidney literature lists Perazella among the leading contributors.
Verify
Representative recent papers, and this author’s full PubMed bibliography.
A code-tallied bibliometric profile from PubMed + NIH iCite, restricted to human/clinical papers across a 15,329-article corpus (regenerated 2026-08-02). Recognition of published contribution — not a verdict on merit or influence, and not medical advice.